Our Long-Term ESG Strategy

Integrated ESG Approach

• Nominating and Corporate Governance Committee oversees ESG strategy and policies

Commitment to U.N. Sustainable Development Goals

  • Created a Global Corporate Sustainability and Social Impact Team in 2021
  • Performed ESG materiality assessment for GW​ business following the acquisition by Jazz
  • Aligning strategy and reporting with UN SDGs and SASB standards, respectively

Environmental

Social

Governance

  • Long-standingcommitment to sustainable practices in manufacturing processes
    • Extensive rainwater harvesting at our cannabis growing operations (utilize or recapture 98%)
    • Jazz produces less than 650 kg CO2 (Scope 1 & 2 GHG emissions) per kg of dried cannabis flower compared to 3,697 kg CO2 per kg of flower from the average U.S. cannabis cultivation site*
    • Use green chemistry principles in our first in- house commercial production site (Athlone, IRE)
    • New buildings meet highest level of sustainability standards (BREEAM)
  • Focused on expanding environmental disclosures

*Source - https://www.arcgis.com/apps/webappviewer/index.html?id=f47100de3f6b46bb9aebf8dc52d957bf&extent=-18880993.9285%2C2754896.1724%2C-8069740.6478%2C10092850.8878%2C102100

  • Increase the diversity of our global workforce by providing an inclusive environment highlighted by the creation of 5 unique Employee Resource Teams (Black, Asian and Pacific Islander, LGBTQ+, LatinX/Hispanic, and Women employees + allies)
  • Focused on attracting the best talent, supporting employee well-being through personal development practices/tools and enhanced benefit programs
  • Ongoing employee engagement through interactive forums with company leadership and pulse surveys (~ 80% response rate). Engagement surveys indicate employees experience an inclusive culture
  • Commitment to improving diversity in our clinical trial enrollments and advocating for public policy initiatives that improve access to care and health equity metrics
  • Lead Independent
    Director with clearly defined responsibilities
  • 11 of 12 directors are independent
  • Annual Board and Committee self- evaluations

Board Refreshment

2 New Independent Directors

added since 2020

Jennifer Cook

Mark Smith, M.D.

Former CEO at

Professor of Clinical

GRAIL, Inc.

Medicine at UC San

Francisco

  • Anti-hedging /pledging / claw back policies
  • Majority vote standard
  • Share ownership requirements
  • 50% of executive target equity is performance based

Director Diversity

POC LGBTQ+

Other Female

50% Diversity in Director Slate

UN SDGs = United Nations Sustainable Development Goals

1

January 2022

SASB = Sustainability Accounting Standards Board

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Jazz Pharmaceuticals plc published this content on 07 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 January 2022 21:37:04 UTC.